Drug Combination Details
| General Information of the Combination (ID: C62469) | |||||
|---|---|---|---|---|---|
| Name | Cryptotanshinone NP Info | + | Gefitinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | GABPA | Molecule Info | |||
| Down-regulation | Expression | TK | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | ||
| NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
| A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | |||
| In-vivo Model | H1975 human lung cancer cells (5 * 107 in 1 ml) or PC9/GR human lung cancer cells (3 * 107 in 1 ml) were injected subcutaneously into the right flank of athymic BALB/c nude mice (3-4 weeks old). | |||||
| Experimental
Result(s) |
Cryptotanshinone strengthens the effect of gefitinib against non-small cell lung cancer through inhibiting transketolase. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Cryptotanshinone strengthens the effect of gefitinib against non-small cell lung cancer through inhibiting transketolase. Eur J Pharmacol. 2021 Jan 5;890:173647. | |||
